JP6506172B2 - 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法 - Google Patents

黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法 Download PDF

Info

Publication number
JP6506172B2
JP6506172B2 JP2015540852A JP2015540852A JP6506172B2 JP 6506172 B2 JP6506172 B2 JP 6506172B2 JP 2015540852 A JP2015540852 A JP 2015540852A JP 2015540852 A JP2015540852 A JP 2015540852A JP 6506172 B2 JP6506172 B2 JP 6506172B2
Authority
JP
Japan
Prior art keywords
seq
antibody
nos
aureus
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015540852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536951A5 (enExample
JP2015536951A (ja
Inventor
セルマン，ブレット
トカチク，クリスティーン
ハミルトン，メリッサ
ホワ，レイ
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2015536951A publication Critical patent/JP2015536951A/ja
Publication of JP2015536951A5 publication Critical patent/JP2015536951A5/ja
Priority to JP2019063358A priority Critical patent/JP6926138B2/ja
Application granted granted Critical
Publication of JP6506172B2 publication Critical patent/JP6506172B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015540852A 2012-11-06 2013-11-05 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法 Active JP6506172B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019063358A JP6926138B2 (ja) 2012-11-06 2019-03-28 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06
US61/723,128 2012-11-06
PCT/US2013/068385 WO2014074470A1 (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019063358A Division JP6926138B2 (ja) 2012-11-06 2019-03-28 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法

Publications (3)

Publication Number Publication Date
JP2015536951A JP2015536951A (ja) 2015-12-24
JP2015536951A5 JP2015536951A5 (enExample) 2016-12-22
JP6506172B2 true JP6506172B2 (ja) 2019-04-24

Family

ID=50685101

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015540852A Active JP6506172B2 (ja) 2012-11-06 2013-11-05 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法
JP2019063358A Active JP6926138B2 (ja) 2012-11-06 2019-03-28 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019063358A Active JP6926138B2 (ja) 2012-11-06 2019-03-28 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法

Country Status (13)

Country Link
US (3) US9845348B2 (enExample)
EP (1) EP2928490B1 (enExample)
JP (2) JP6506172B2 (enExample)
KR (3) KR20210083389A (enExample)
CN (2) CN112316135A (enExample)
AU (2) AU2013341421A1 (enExample)
BR (1) BR112015010126B1 (enExample)
CA (1) CA2890385C (enExample)
ES (1) ES2912267T3 (enExample)
MX (1) MX367082B (enExample)
RU (1) RU2661406C2 (enExample)
SG (2) SG11201503231YA (enExample)
WO (1) WO2014074470A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57024B1 (sr) 2011-06-10 2018-05-31 Medimmune Ltd Anti-pseudomonas psl vezujući molekuli i njihova upotreba
US10597439B2 (en) 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
CN104968797B (zh) * 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
JP6506172B2 (ja) * 2012-11-06 2019-04-24 メディミューン，エルエルシー 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
US11155606B2 (en) 2018-07-24 2021-10-26 Medimmune, Llc Antibody directed against S. aureus clumping factor a (ClfA)
WO2020076790A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
BR112021006622A2 (pt) 2018-10-09 2021-07-20 Medimmune, Llc combinações de anticorpos anti-staphylococcus aureus
US12264194B2 (en) 2019-03-13 2025-04-01 Medimmune, Llc Decreasing Staphylococcus aureus infections in colonized patients
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053235A1 (en) * 2006-06-12 2009-02-26 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
JP5658564B2 (ja) * 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
WO2011008939A2 (en) * 2009-07-16 2011-01-20 Medical College Of Georgia Research Institute, Inc. Porous-wall hollow glass microspheres as carriers for biomolecules
EP2284193A1 (en) 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
CA2825770A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
BR112013020086B1 (pt) * 2011-02-08 2020-12-08 Medimmune, Llc Anticorpo isolado ou seu fragmento de ligação a antígeno, composição compreendendo o anticorpo ou fragmento de ligação a antígeno, kit, uso de uma quantidade eficaz de um anticorpo ou seu fragmento de ligação a antígeno e método para inibir a formação da oligômeros de alfatoxina
CN104968797B (zh) 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
JP6506172B2 (ja) * 2012-11-06 2019-04-24 メディミューン，エルエルシー 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Also Published As

Publication number Publication date
KR102272744B1 (ko) 2021-07-06
JP6926138B2 (ja) 2021-08-25
MX367082B (es) 2019-08-05
SG10201703677VA (en) 2017-06-29
EP2928490A4 (en) 2016-11-02
KR20150092738A (ko) 2015-08-13
SG11201503231YA (en) 2015-05-28
AU2018236849A1 (en) 2018-10-18
CN112316135A (zh) 2021-02-05
BR112015010126A2 (enExample) 2017-08-22
BR112015010126B1 (pt) 2022-11-01
US10759849B2 (en) 2020-09-01
US20190002540A1 (en) 2019-01-03
WO2014074470A1 (en) 2014-05-15
JP2019142888A (ja) 2019-08-29
CA2890385C (en) 2022-07-12
RU2015121617A (ru) 2016-12-27
CA2890385A1 (en) 2014-05-15
ES2912267T3 (es) 2022-05-25
US9845348B2 (en) 2017-12-19
EP2928490A1 (en) 2015-10-14
JP2015536951A (ja) 2015-12-24
EP2928490B1 (en) 2022-03-30
US20160257733A1 (en) 2016-09-08
US20200109191A1 (en) 2020-04-09
AU2013341421A1 (en) 2015-06-04
US10457724B2 (en) 2019-10-29
HK1215173A1 (zh) 2016-08-19
CN104780934A (zh) 2015-07-15
MX2015005481A (es) 2016-01-14
RU2661406C2 (ru) 2018-07-16
AU2018236849B2 (en) 2020-05-21
KR20210083389A (ko) 2021-07-06
KR20200102533A (ko) 2020-08-31

Similar Documents

Publication Publication Date Title
US10759849B2 (en) Methods of treating S. aureus-associated diseases
KR102288394B1 (ko) 스타필로코커스 아우레우스 표면 결정인자에 대한 항체
AU2015276938B2 (en) Treatment of polybacterials infections
US20150044168A1 (en) Treatment of Multiple Sclerosis With Anti-CD19 Antibody
JP2022512647A (ja) 抗黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）抗体の組み合わせ
CA3121934A1 (en) Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant
JP2025515485A (ja) 眼の疾患を治療するための組成物及び方法
HK1215173B (en) Methods of treating s. aureus-associated diseases
RU2804815C2 (ru) Комбинации антител к staphylococcus aureus
TW202511292A (zh) 用於治療ＮＳＣＬＣ及ｃＨＬ之ＰＤ－１／ＴＩＭ－３結合蛋白
HK40025295A (en) Antibodies to s. aureus surface determinants
HK1215452B (zh) 金黃色葡萄球菌表面決定簇的抗體
HK1236126A1 (en) Treatment of polybacterials infections
HK1236126B (en) Treatment of polybacterials infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190328

R150 Certificate of patent or registration of utility model

Ref document number: 6506172

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250